Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

Inclusion Criteria:

• Male or female age 18-75 years (both inclusive) at time of signing informed consent

• Body mass index of 18.5-29.9 kg/m^2 (both inclusive)

• A good general health based on medical history, physical examination, and results ofvital signs, electrocardiogram and laboratory safety tests performed during thescreening visit, as judged by the investigator

Exclusion Criteria:

• Female who is pregnant, breast-feeding or intends to become pregnant or is ofchild-bearing potential and not using adequate contraceptive methods. Female of childbearing potential must use effective methods of birth control for the duration of thetrial and for 5 weeks following last dose. Only highly effective methods of birthcontrol are accepted (i.e., one that results in a less than 1% per year failure ratewhen used consistently and correctly, such as implants, injectables, combined oralcontraceptives, and some intrauterine devices)

• History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease

• Hypertension (defined as sitting systolic blood pressure above or equal to 140 mmHgand/or diastolic blood pressure above or equal to 90 mmHg). If white-coat hypertensionis suspected at the screening visit a repeated measurement is allowed

• Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma inexcess of 400 mL within the 3 months preceding screening